AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

  • End date
    Jun 27, 2024
  • participants needed
  • sponsor
Updated on 25 March 2022


At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia


This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia The study will be conducted in five parts.

Condition Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Treatment Itraconazole, Azacitidine, AMG 176
Clinical Study IdentifierNCT02675452
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

For participants in Japan only: if a participant is younger than 20 years at the time of signing the informed consent form, informed consent must be obtained from both the participant and his/her legal representative
(Multiple myeloma [MM] participants) Pathologically documented, multiple myeloma relapsed or refractory disease after at least 2 lines of therapy
(MM participants only) Measurable disease per the International Myeloma Working Group response criteria
(Acute myeloid leukemia [AML] participants) AML as defined by the World Health Organization Classification persisting or recurring following one or more treatment courses, and for participants in Japan, determined by the investigator to be not eligible for approved anticancer drug therapy in Japan; EXCEPT acute promyelocytic leukemia
(AML participants only) More than 5% blasts in bone marrow and Circulating white blood cells < 25,000/ul
Must be willing and able to undergo a core bone marrow biopsy (MM participants only) and bone marrow aspirate (MM and AML participants) at screening
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
(MM partiicpants only) Satisfactory hematological function without transfusion or growth factor support
Life expectancy of > 3 months, in the opinion of the investigator
Adequate hepatic function
Adequate cardiac function
Adequate renal function
Female participants of childbearing potential must have a negative serum or urine pregnancy test
Other inclusion criteria may apply

Exclusion Criteria

Previously received an allogeneic stem cell transplant within 6 months OR having received immunosuppressive therapy within the last three months OR having signs or symptoms of acute or chronic graft-versus-host disease
Autologous stem cell transplant less than 90 days prior to study day 1
(MM participants only) MM with Immunoglobulin M subtype
(MM participants only) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome
(MM participants only) Existing plasma cell leukemia
(MM participants only) Waldenstrom's macroglobulinemia
(MM participants only) Amyloidosis
Infection requiring intravenous anti-infective treatments within 1 week of study enrollment (day 1)
Myocardial infarction within 6 months of enrollment, symptomatic congestive heart failure (New York Heart Association > class II)
History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6 months prior to enrollment
Currently receiving treatment in another investigational device or drug study. Other investigational procedures while participating in this study will be allowed if approved by Amgen medical monitor
Participants with elevated cardiac troponin above the manufacturer's 99th percentile upper reference limit for ADVIA Centaur XP assay at screening performed by the central laboratory
Participants with evidence of recent cardiac injury at screening based on creatine kinase-muscle/brain, N-terminal prohormone of brain natriuretic peptide, and electrocardiogram
Other exclusion criteria may apply
(AML Part 3d only) History of QT prolongation, torsades de pointes, ventricular tachycardia and cardiac arrest
History or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection unless agreed upon with medical monitor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note